Skip to main content

Table 1 Characteristics of the included studies

From: The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Study

Year

Location

Number (age)a

Drug (dosage)

Durationb

UDCA Monotherapy

Laurin et al. [24]

1996

USA

25 (46 y) vs. 16 (50 y)

UDCA (13-15 mg/kg/d)/Clofibrate (1 g twice daily)

12 m

Lindor et al. [25]

2004

USA/Canada

80 (45.4 y) vs. 86 (48.5 y)

UDCA (13-15 mg/kg/d)/placebo (tablet)

24 m

Dufour et al. [20]

2006

Switzerland

18 (47 y) vs. 15 (45 y)

UDCA (13-15 mg/kg/d)/placebo (tablet)

24 m

Kiyici et al. [26]

2003

Turkey

17 (43.7 y) vs. 27 (50.2 y)

UDCA (13-15 mg/kg/d)/Atorvastatin (10 mg/d)

6 m

Hong Qian, et al. [32]

2007

China

26 vs. 26

UDCA (15-20 mg/kg/d)/polyene phosphatidylcholine (1368 mg/d)

6 m

Zhu Hong-juan [27]

2010

China

30 (42.5 y) vs. 30 (43.6 y)

UDCA (750 mg/d)/placebo (tablet)

2 m

Ratziu et al. [28]

2011

France

55 (49.8 y) vs. 61 (49.6 y)

UDCA (28-35 mg/kg/d)/placebo (tablet)

12 m

Leuschner et al. [29]

2010

Germany

94 (41.5 y) vs. 91 (45.0 y)

UDCA (23-28 mg/kg/d)/placebo (tablet)

18 m

UDCA combined with other drugs

Dufour et al. [20]

2006

Switzerland

15 (46 y) vs. 15 (45 y)

UDCA (13-15 mg/kg/d) + Vitamin E (400 IU/d)/placebo (tablet)

24 m

Zhuang Xue-shan [30]

2009

China

40 vs. 42

UDCA (750 mg/d) + polyene phosphatidylcholin (1368 mg/d)/polyene phosphatidylcholine (1368 mg/d)

6 m

Sun Yan [31]

2007

China

76 vs. 61

UDCA (300 mg/d) + Silymarin (231 mg/d)/Silymarin (231 mg/d)

3 m

Lv Hong [33]

2005

China

40 vs. 40

UDCA (450 mg/d) + glycyrrhizin (450 mg/d)/placebo (tablet)

2 m

Liu Zhi-ye [34]

2006

China

96 (42.5 y) vs. 54 (47.6 y)

UDCA (900 mg/d) + Tiopronin (600 mg/d)/ UDCA (900 mg/d)

3 m

  1. anumber and mean age were displayed as treatment: control group; bduration reported in months; blue indicates a higher dose of UDCA.